Vegaspan
Clear, colorless or light yellow slightly viscous liquid containing easily resuspendable white or almost white particles, free from foreign matter. When shaken, a stable suspension of white or yellowish color is formed.
One ampoule contains:
active substances: betamethasone sodium phosphate (in terms of 100% dry matter) 2.63 mg (equivalent to 2.0 mg of betamethasone), betamethasone dipropionate (in terms of 100% dry matter) 6.43 mg (equivalent to 5.0 mg betamethasone)
excipients: methyl parahydroxybenzoate (nipagin, E218), propyl parahydroxybenzoate (nipazole, E 216), benzyl alcohol, sodium chloride, sodium hydrogen phosphate dihydrate, disodium edetate (Trilon B), sodium carmellose (sodium carboxymethylcellulose), polysorbate 80, polyethylene glycol 4000, hydrochloric acid, water for injection.
Musculoskeletal system and soft tissues: rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, sciatica, coccydia (pain in the coccyx), sciatica, lumbago, acute gouty arthritis, torticollis, ganglion cyst, exostosis (growth of bone and cartilage tissue) and fasciitis.
Allergic diseases: chronic bronchial asthma (including in the complex therapy of status asthmaticus), hay fever, angioedema, severe allergic bronchitis, contact dermatitis, atopic dermatitis, seasonal or perennial allergic rhinitis, drug reactions, serum sickness and reactions caused by drugs or insect bites.
Dermatological diseases: atopic dermatitis (monetary eczema), neurodermatitis (shingles simplex), contact dermatitis, severe solar dermatitis, urticaria, hypertrophic lichen planus, diabetic lipodystrophy, alopecia areata, discoid lupus erythematosus, psoriasis, keloid scars, pemphigus vulgaris, herpetiformis dermatitis and cystic acne.
Collagenoses: systemic lupus erythematosus, scleroderma, dermatomyositis and periarteritis nodosa.
Neoplastic diseases: as a palliative treatment for leukemias and lymphomas in adults; acute leukemia in children.
Other conditions: adrenogenital syndrome, ulcerative colitis, Crohn’s disease, sprue, pediatric disorders (subdural bursitis, stiff big toe, varus toes), conditions requiring subconjunctival injections, corticosteroid-dependent blood disorders, nephritis, and nephrotic syndrome.
Primary or secondary adrenal insufficiency (with mandatory simultaneous administration of mineralocorticosteroids).
The dosage regimen and method of administration are set individually, depending on the indications, the severity of the disease and the patient’s response to treatment.
Vegaspan is recommended for:
- intramuscular injections for diseases that respond to the action of systemic corticosteroids;
- direct injections into the affected soft tissues according to indications;
- intraarticular and periarticular injections for arthritis;
- interstitial injections for various dermatological diseases;
- local injections for some inflammatory and cystic diseases of the foot.
Shake well before administration.
Dosage:
The dose should be minimal, the period of application should be as short as possible.
The dose should be adjusted until a satisfactory clinical response is obtained. If there is no satisfactory clinical response after a certain period of time, Vegaspan should be discontinued by gradual dose reduction and another therapy should be instituted.
After achieving a therapeutic effect, the maintenance dose is selected by gradually reducing the dose administered at certain time intervals until the minimum dose is reached, providing an adequate clinical effect.
Method of administration:
Vegaspan should not be used for intravenous or
subcutaneous injection.
With systemic therapy, the initial dose of Vegaspan in most cases is 1-2 ml. The introduction is repeated as necessary, depending on the condition of the patient. The introduction is carried out by deep intramuscular (IM) injection into the gluteal region. Dosages and frequency of administration are selected individually, taking into account the severity of the patient’s condition and the therapeutic response:
– in severe conditions (lupus erythematosus and status asthmaticus) requiring emergency measures, the initial dose of the drug may be 2 ml;
– in dermatological diseases, as a rule, 1 ml of the drug is sufficient, depending on the therapeutic response, its administration can be repeated;
– in diseases of the respiratory system, the action of the drug Vegaspan begins within a few hours after intramuscular injection of the drug. With bronchial asthma, hay fever, allergic bronchitis and allergic rhinitis, a significant improvement in the condition is achieved after the introduction of 1-2
ml of the drug;
– in acute and chronic bursitis, the initial dose for intramuscular injection is 1-2 ml of the drug. If necessary, the drug is administered repeatedly.
With local administration, the simultaneous use of a local anesthetic is rarely required. When administered simultaneously with a local anesthetic, Vegaspan can be mixed in a syringe (not in a vial) with a 1% or 2% solution of procaine hydrochloride or lidocaine using paraben-free formulations. Similar local anesthetics may also be used. It is not allowed to use anesthetics that contain methylparaben, propylparaben, phenol and other similar substances. When using an anesthetic in combination with Vegaspan, first the necessary dose of the drug is drawn into the syringe from the vial, then the required amount of local anesthetic is drawn into the same syringe from the ampoule and shaken for a short period of time.
In acute bursitis (subdeltoid, subscapular, ulnar, and prepatellar), instillation of 1-2 ml of Vegaspan into the bursa can relieve pain and restore full mobility within a few hours.
Once acute symptoms subside, chronic bursitis can be treated with low doses of Vegaspan.
In the case of acute conditions such as tenosynovitis, tendonitis and peritendinitis, the administration of Vegaspan should improve the symptoms of the disease. In chronic forms of these conditions, depending on the condition of each individual patient, a second injection may be required.
After an intra-articular dose of Vegaspan 0.5-2 ml, within two to four hours, pain and stiffness caused by rheumatoid arthritis and osteoarthritis can be relieved. In both conditions, in most cases, the duration of symptom relief, with great variation, is four weeks or more.
Intra-articular administration of Vegaspan is well tolerated by articular and periarticular tissues. Recommended doses of the drug for injection into large joints (knee, hip, shoulder) -1-2 ml; for medium joints (elbow, wrist, ankle) – 0.5-1 ml; for small joints (foot, arm, chest) – 0.25-0.5 ml. Dermatological conditions may respond to intralesional administration of Vegaspan. The reaction of some lesions that are not amenable to direct treatment may be associated with a weak systemic effect of the drug.
In some skin diseases, intradermal administration of the drug directly into the lesion is effective, the dose is 0.2 ml / cm2. The lesion site is evenly cut off using a tuberculin syringe and a 26 G needle. The total dose of the drug injected into all injection sites for 1 week should not exceed 1 ml. In certain conditions, such as stiff toe, varus toe, and acute gouty arthritis, relief comes quickly. For most injections, a tuberculin syringe and a 25-gauge needle are recommended.
Recommended single doses of Vegaspan (once a week):
– with hard callus – 0.25 ml (as a rule, 2 consecutive injections are made);
– with a spur – 0.5 ml;
– with stiffness of the big toe – 0.5 ml;
– with a synovial cyst – from 0.25 to 0.5 ml;
– with tendosynovitis – 0.5 ml;
– in acute gouty arthritis – from 0.5 to 1 ml.
After achieving a therapeutic effect, the maintenance dose is selected by gradually reducing the initial dose at certain time intervals until the minimum effective dose is reached.
Exposure of the patient to stressful situations (which are not associated with the disease) may require an increase in the dose of Vegaspan.
Cancellation of the drug after prolonged therapy should be carried out by gradually reducing the dose. In children during the period of growth, corticosteroids should be used only when absolutely indicated under the very careful supervision of the attending physician.
Composition
One ampoule contains:
active substances: betamethasone sodium phosphate (in terms of 100% dry matter) 2.63 mg (equivalent to 2.0 mg of betamethasone), betamethasone dipropionate (in terms of 100% dry matter) 6.43 mg (equivalent to 5.0 mg betamethasone)
excipients: methyl parahydroxybenzoate (nipagin, E218), propyl parahydroxybenzoate (nipazole, E 216), benzyl alcohol, sodium chloride, sodium hydrogen phosphate dihydrate, disodium edetate (Trilon B), sodium carmellose (sodium carboxymethylcellulose), polysorbate 80, polyethylene glycol 4000, hydrochloric acid, water for injection.
Indications for use
Musculoskeletal system and soft tissues: rheumatoid arthritis, osteoarthritis, bursitis, ankylosing spondylitis, epicondylitis, sciatica, coccydia (pain in the coccyx), sciatica, lumbago, acute gouty arthritis, torticollis, ganglion cyst, exostosis (growth of bone and cartilage tissue) and fasciitis.
Allergic diseases: chronic bronchial asthma (including in the complex therapy of status asthmaticus), hay fever, angioedema, severe allergic bronchitis, contact dermatitis, atopic dermatitis, seasonal or perennial allergic rhinitis, drug reactions, serum sickness and reactions caused by drugs or insect bites.
Dermatological diseases: atopic dermatitis (monetary eczema), neurodermatitis (shingles simplex), contact dermatitis, severe solar dermatitis, urticaria, hypertrophic lichen planus, diabetic lipodystrophy, alopecia areata, discoid lupus erythematosus, psoriasis, keloid scars, pemphigus vulgaris, herpetiformis dermatitis and cystic acne.
Collagenoses: systemic lupus erythematosus, scleroderma, dermatomyositis and periarteritis nodosa.
Neoplastic diseases: as a palliative treatment for leukemias and lymphomas in adults; acute leukemia in children.
Other conditions: adrenogenital syndrome, ulcerative colitis, Crohn’s disease, sprue, pediatric disorders (subdural bursitis, stiff big toe, varus toes), conditions requiring subconjunctival injections, corticosteroid-dependent blood disorders, nephritis, and nephrotic syndrome.
Primary or secondary adrenal insufficiency (with mandatory simultaneous administration of mineralocorticosteroids).
Mode of application
The dosage regimen and method of administration are set individually, depending on the indications, the severity of the disease and the patient’s response to treatment.
Vegaspan is recommended for:
- intramuscular injections for diseases that respond to the action of systemic corticosteroids;
- direct injections into the affected soft tissues according to indications;
- intraarticular and periarticular injections for arthritis;
- interstitial injections for various dermatological diseases;
- local injections for some inflammatory and cystic diseases of the foot.
Shake well before administration.
Dosage:
The dose should be minimal, the period of application should be as short as possible.
The dose should be adjusted until a satisfactory clinical response is obtained. If there is no satisfactory clinical response after a certain period of time, Vegaspan should be discontinued by gradual dose reduction and another therapy should be instituted.
After achieving a therapeutic effect, the maintenance dose is selected by gradually reducing the dose administered at certain time intervals until the minimum dose is reached, providing an adequate clinical effect.
Method of administration:
Vegaspan should not be used for intravenous or
subcutaneous injection.
With systemic therapy, the initial dose of Vegaspan in most cases is 1-2 ml. The introduction is repeated as necessary, depending on the condition of the patient. The introduction is carried out by deep intramuscular (IM) injection into the gluteal region. Dosages and frequency of administration are selected individually, taking into account the severity of the patient’s condition and the therapeutic response:
– in severe conditions (lupus erythematosus and status asthmaticus) requiring emergency measures, the initial dose of the drug may be 2 ml;
– in dermatological diseases, as a rule, 1 ml of the drug is sufficient, depending on the therapeutic response, its administration can be repeated;
– in diseases of the respiratory system, the action of the drug Vegaspan begins within a few hours after intramuscular injection of the drug. With bronchial asthma, hay fever, allergic bronchitis and allergic rhinitis, a significant improvement in the condition is achieved after the introduction of 1-2
ml of the drug;
– in acute and chronic bursitis, the initial dose for intramuscular injection is 1-2 ml of the drug. If necessary, the drug is administered repeatedly.
With local administration, the simultaneous use of a local anesthetic is rarely required. When administered simultaneously with a local anesthetic, Vegaspan can be mixed in a syringe (not in a vial) with a 1% or 2% solution of procaine hydrochloride or lidocaine using paraben-free formulations. Similar local anesthetics may also be used. It is not allowed to use anesthetics that contain methylparaben, propylparaben, phenol and other similar substances. When using an anesthetic in combination with Vegaspan, first the necessary dose of the drug is drawn into the syringe from the vial, then the required amount of local anesthetic is drawn into the same syringe from the ampoule and shaken for a short period of time.
In acute bursitis (subdeltoid, subscapular, ulnar, and prepatellar), instillation of 1-2 ml of Vegaspan into the bursa can relieve pain and restore full mobility within a few hours.
Once acute symptoms subside, chronic bursitis can be treated with low doses of Vegaspan.
In the case of acute conditions such as tenosynovitis, tendonitis and peritendinitis, the administration of Vegaspan should improve the symptoms of the disease. In chronic forms of these conditions, depending on the condition of each individual patient, a second injection may be required.
After an intra-articular dose of Vegaspan 0.5-2 ml, within two to four hours, pain and stiffness caused by rheumatoid arthritis and osteoarthritis can be relieved. In both conditions, in most cases, the duration of symptom relief, with great variation, is four weeks or more.
Intra-articular administration of Vegaspan is well tolerated by articular and periarticular tissues. Recommended doses of the drug for injection into large joints (knee, hip, shoulder) -1-2 ml; for medium joints (elbow, wrist, ankle) – 0.5-1 ml; for small joints (foot, arm, chest) – 0.25-0.5 ml. Dermatological conditions may respond to intralesional administration of Vegaspan. The reaction of some lesions that are not amenable to direct treatment may be associated with a weak systemic effect of the drug.
In some skin diseases, intradermal administration of the drug directly into the lesion is effective, the dose is 0.2 ml / cm2. The lesion site is evenly cut off using a tuberculin syringe and a 26 G needle. The total dose of the drug injected into all injection sites for 1 week should not exceed 1 ml. In certain conditions, such as stiff toe, varus toe, and acute gouty arthritis, relief comes quickly. For most injections, a tuberculin syringe and a 25-gauge needle are recommended.
Recommended single doses of Vegaspan (once a week):
– with hard callus – 0.25 ml (as a rule, 2 consecutive injections are made);
– with a spur – 0.5 ml;
– with stiffness of the big toe – 0.5 ml;
– with a synovial cyst – from 0.25 to 0.5 ml;
– with tendosynovitis – 0.5 ml;
– in acute gouty arthritis – from 0.5 to 1 ml.
After achieving a therapeutic effect, the maintenance dose is selected by gradually reducing the initial dose at certain time intervals until the minimum effective dose is reached.
Exposure of the patient to stressful situations (which are not associated with the disease) may require an increase in the dose of Vegaspan.
Cancellation of the drug after prolonged therapy should be carried out by gradually reducing the dose. In children during the period of growth, corticosteroids should be used only when absolutely indicated under the very careful supervision of the attending physician.